Literature DB >> 16341957

Secondary prevention in coronary heart disease: goal achievement and drug prescribing.

Trude Giverhaug1, Christine Bruland, Thor Trovik.   

Abstract

OBJECTIVE: To provide an overview of the degree of treatment goal achievement and drug prescribing in patients with coronary heart disease (CHD) in clinical practice.
METHOD: Patients undergoing planned or acute percutaneous coronary intervention (PCI) were included. Patients' medical records and the hospital's database on clinical chemistry analyses were studied retrospectively. MAIN OUTCOME MEASURE: Goal achievement and drug prescription relative to published therapeutic guidelines.
RESULTS: A total of 200 patients aged 66 +/- 11 years were included. Blood pressure <140/90 mmHg was achieved in 36% of patients 3 months after PCI and total cholesterol <5 mmol/l was achieved in 29% at the time of PCI. Three months after PCI the patients were on 1.4 (range 0-4) drugs with antihypertensive effect (including diuretics). Seventy eight percent were on a statin, 92% were on low-dose aspirin, and 23% had a diuretic in their drug regimen. Five out of 16 patients with diabetes mellitus included in the study were prescribed an angiotensin converting enzyme-inhibitor (ACE-I).
CONCLUSION: There is probably a potential for increased degree of goal achievement and for improved drug prescribing in patients with CHD undergoing PCI at our hospital.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16341957     DOI: 10.1007/s11096-005-1312-1

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  9 in total

1.  Report of the expert committee on the diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

2.  Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention.

Authors: 
Journal:  Eur Heart J       Date:  1998-10       Impact factor: 29.983

3.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

4.  Drug therapy for prevention of recurrent myocardial infarction.

Authors:  Menno E van der Elst; Henk Buurma; Marcel L Bouvy; Anthonius de Boer
Journal:  Ann Pharmacother       Date:  2003-10       Impact factor: 3.154

5.  Guidelines for the management of patients with chronic stable angina: treatment.

Authors:  S D Fihn; S V Williams; J Daley; R J Gibbons
Journal:  Ann Intern Med       Date:  2001-10-16       Impact factor: 25.391

6.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

Authors: 
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

7.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

8.  British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary.

Authors:  Bryan Williams; Neil R Poulter; Morris J Brown; Mark Davis; Gordon T McInnes; John F Potter; Peter S Sever; Simon McG Thom
Journal:  BMJ       Date:  2004-03-13

9.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.